Management tracks: Vertex’s Graney joins Generation Bio

Tom Graney has left Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as CFO to take on the same role at non-viral gene therapy company Generation Bio Co. (Cambridge, Mass.). Ian Smith, Vertex EVP and COO and former CFO, has become interim CFO, according to a regulatory filing.

Generation Bio’s previous CFO, Glenn Goddard, left in October to join CRISPR company Intellia Therapeutics Inc. (NASDAQ:NTLA). Generation Bio launched in January with a $25 million series A and raised $100 million in a series B round in February led by crossover investor Fidelity (see "Going Non-Viral"). ...